As the demand for high-performance nutritional ingredients continues to grow, NNB Nutrition has established itself as a global leader and trusted L-Citrulline...
As the global focus on metabolic health continues to grow, GlucoVantage has emerged as a breakthrough ingredient in blood sugar and weight management. Marketed as...
In the fast-growing sports nutrition industry, ingredient stability and performance are critical to both manufacturers and consumers. NNB Nutrition, a leading...
Read Full Article at:...
NNB Nutrition (https://nnbnutrition.com/), a cutting-edge branded ingredient supplier and creator, known for its R&D and innovative ability, has recently released new experimental research on EGT’s senostatic function. This research once again proved MitoPrime®’s effectiveness in anti-aging and cellular health. MitoPrime® as one of NNB’s star ingredients has obtained 15 patents including its effectiveness on muscle degeneration, age-related macular degeneration, and improving skin luminosity. NNB is planning to file for more patents and do more research to explore MitoPrime®’s efficacy in various aspects.
MitoBurn®(L-BAIBA,β-aminoisobutyric acid), known as an “exercise factor”, increased levels of L-BAIBA are associated with many of exercise’s numerous benefits. L-BAIBA helps regulate metabolism, increase energy expenditure, manage fuel selection, support the production of ketones, etc.
NNB Nutrition (https://nnbnutrition.com/), a cutting-edge branded ingredient supplier and creator, delivers new and novel ingredients with an elite global team of scientists, recently announced that they have filed a PCT patent (PCT/CN2021/101541)on the use of MitoPrime®(L-Ergothioneine) to alleviate and prevent age-related macular degeneration(AMD). In this patent’s research, NNB discovered that MitoPrime can actively prevent age-associated visual degeneration in the mammal.
On May 13, 2022, a toxicity study Published by NNB (https://journals.sagepub.com/doi/abs/10.1177%2F10915818221094487) was designed to evaluate the safety and toxic potentials of MitoBurn(L-BAIBA), where L-BAIBA was administered orally to Sprague Dawley rats at 100, 300, and 900 mg/kg/day for 90 days. The study shows that no treatment-related adverse effects were observed in any of the treatment groups. Based on the results, the No-Observed-Adverse-Effect Level (NOAEL) of L-BAIBA was 900 mg/kg/day. This study is the first study to access the safety profile of L-BAIBA in an in vivo repeated dose subchronic toxicity stud by oral (gavage) route in Sprague Dawley rats.
On 11 July, 2022, a toxicological assessment of GlucoVantage® (Dihydroberberine) was published by NNB on Elsevier, the authoritative academic journal. This study were conducted at Vedic Lifesciences, Pvt. Ltd., Mumbai, India. All studies were sponsored by NNB Nutrition, 90-day sub-chronic toxicity study with a 28-day recovery period the NOAEL for GlucoVantage® was found to be 100 mg/kg bw/day, which was the highest dose tested. None of the animals in the study died prematurely and noclinical signs were associated with GlucoVantage®, indicating that GlucoVantage® is safe to use in human and exhibited greater bioavailiability than BBR.
MitoPrime®(L-Ergothioneine), the New“Longevity Vitamin”, employs the Previously Unknown Nutrient Transporter ETT (OCTN1). L-Ergothioneine is often considered the most comprehensive oral Antioxidant known, which exhibits profound anti-inflammatory actions and protects DNA & mtDNA. NNB Nutrition (https://nnbnutrition.com/), a cutting-edge branded ingredient supplier and creator delivering new and novel ingredients with an elite global team of scientists, announces that it has filed a PCT patent (PCT/CN2022/074500) on proprietary MitoPrime’s benefits with mitigating skin aging. This patent have investigated the safety and efficacy of a composition comprising ergothioneine on alleviating skin aging, and can counteract or delay skin aging signs in a safe and effective way. NNB’s patent studied the safety and efficacy of topica 10% MitoPrime cream in subjects with photoaging. The study researched 28 healthy female subjects 35-70 years of age with Fitzpatrick skin types I-II (Type I: Light, Pale White & Type II: White, Fair, both burns easily) and mild to moderate photoaging, within the 12 weeks, subjects were asked to use 10% MitoPrime Moisturizer on half of face, and Bland Moisturizer on another half of face, with placebo control. The result showed that MitoPrime have overall appearance improvement in skin’s radiance, luminosity, and texture. The result also demonstrated that there’s no statistically significant tolerability issues noted at any time point, thus proved that MitoPrime had no significant adverse reactions.